Personalized immune cells engineered to fight tough ovarian cancer
Disease control
Recruiting now
This early-stage trial is testing a new personalized cell therapy called OPB-101 for women with ovarian cancer that has stopped responding to standard platinum-based chemotherapy. Doctors will modify a patient's own immune cells in a lab to target the cancer and then infuse them …
Phase: PHASE1 • Sponsor: Outpace Bio, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC